Entry point for public reimbursement Using the reduced off-patent price as a strong argument for increased access, Canada could become the first market with wide-scale reimbursement of existing primary care medicines, including GLP-1s for diabetes, to designate off-patent semaglutide as the first-line anti-obesity medication (AOM)
Our team of skilled licensed healthcare practitioners are experienced and well-versed in a wide array of conditions and ailments that they can provide guidance and treatment suggestions about
compounded tirzepatide Zepbound and Mounjaro are FDA-approved, brand-name tirzepatide
Orforglipron is an investigational, non-peptide, oral glucagon-like peptide-1 receptor agonist developed by Eli Lilly
Foods rich in potassium, magnesium, and calcium, such as bananas, spinach, yogurt, and nuts, can help reduce cramps
Di Marzio L, Moretti S, D'Alo S, et al